A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases-Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.
Latest Information Update: 05 Oct 2023
At a glance
- Drugs DDO 3055 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Oct 2021 Planned End Date changed from 4 Mar 2021 to 31 Dec 2021.
- 24 Oct 2021 Planned primary completion date changed from 25 Feb 2021 to 31 Dec 2021.
- 24 Oct 2021 Status changed from not yet recruiting to recruiting.